Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.

Goossens, Nicolas; Bellentani, Stefano; Cerny, Andreas; Dufour, Jean-François; Jornayvaz, François R; Mertens, Joachim; Moriggia, Alberto; Muellhaupt, Beat; Negro, Francesco; Razavi, Homie; Semela, David; Estes, Chris (2019). Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. Swiss medical weekly, 149, w20152. EMH Media 10.4414/smw.2019.20152

[img]
Preview
Text
smw_2019_20152.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (750kB) | Preview

As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term trending of NAFLD prevalence was based on changes in the prevalence of adult obesity. Published estimates and surveillance data were applied to build and validate the model projections. The prevalence of NAFLD increased up to 2030 in tandem with projected increases in adult obesity. By 2030, there were an estimated 2,234,000 (1,918,000–2,553,000) NAFLD cases, or 24.3% (20.9–27.8%) of the total Swiss population (all ages). Increases in NASH cases were relatively greater than NAFLD cases. Incident cases of advanced liver disease are projected to increase by approximately 40% by 2030, and incident NAFLD liver deaths to increase from 580 deaths in 2018 to 820 deaths in 2030. Continued growth in obesity, in combination with an aging population, will result in increasing number of cases of advanced liver disease and mortality related to NAFLD and NASH. Slowing the growth in obesity and metabolic syndrome, along with future potential therapies, are required to reduce liver disease burden. &nbsp.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1424-3997

Publisher:

EMH Media

Language:

English

Submitter:

Thi Thao Anh Pham

Date Deposited:

13 Jan 2020 12:09

Last Modified:

19 Jan 2020 02:48

Publisher DOI:

10.4414/smw.2019.20152

PubMed ID:

31846507

BORIS DOI:

10.7892/boris.137065

URI:

https://boris.unibe.ch/id/eprint/137065

Actions (login required)

Edit item Edit item
Provide Feedback